For decades, systemic hormone therapy (HT) has been the gold standard for managing the physical hallmarks of menopause: the drenching night sweats, the disruptive hot flashes, and the atrophy associated with the genitourinary syndrome of menopause. Yet, for the millions of women navigating the hormonal upheaval of midlife, the most debilitating symptoms are often the ones that cannot be seen—the irritability, the crushing fatigue, and the encroaching fog of anxiety and depression.
A new retrospective observational study, published in the journal Menopause, suggests that hormone therapy may offer a powerful, underutilized lever for addressing these psychological burdens. Led by researchers at the NYU Grossman School of Medicine, the study provides compelling real-world data indicating that systemic HT is associated with significant improvements in mood and sleep quality, potentially broadening the clinical scope of how we treat the menopause transition.
The Core Findings: A Significant Shift in Mental Well-Being
The research, headed by Samantha Fairweather, MD, tracked 260 perimenopausal and postmenopausal patients at NYU Langone Health between January 2023 and April 2025. By analyzing data from the Menopause Rating Scale (MRS)—a standardized tool used to quantify symptom severity—the researchers observed a statistically significant improvement in psychological health following the initiation of systemic hormone therapy.
After a mean follow-up of 4.5 months, patients reported marked reductions in symptoms such as depressive mood, anxiety, irritability, and mental exhaustion. The mean difference in psychological symptom scores was -2.7 on the MRS scale (where 0 represents an asymptomatic state and 4 signifies very severe distress). Perhaps most strikingly, the greatest benefit was observed in those who entered the study with the most severe baseline psychological symptoms, who saw an average score improvement of -3.85.
Beyond mood, the study highlighted a "ripple effect" of treatment: sleep disturbances, which are inextricably linked to mood disorders in the menopausal population, also saw significant improvement. The proportion of patients reporting severe mood symptoms plummeted from 62.3% at the study’s outset to just 24.6% by the follow-up visit.
Chronology and Study Design: Tracking the Transition
The study’s methodology offers a window into "real-world" clinical practice, a departure from the highly controlled, laboratory-based environments of traditional clinical trials.
- January 2023 – April 2025: The study period during which patients were evaluated at the NYU Langone menopause clinic.
- Initial Enrollment: Patients were assessed at their first visit, at which point they were prescribed systemic hormone therapy for FDA-approved indications, such as vasomotor symptom relief or osteoporosis prevention.
- Follow-up: Participants attended at least two clinical visits during the study period, allowing researchers to compare pre-treatment and post-treatment MRS scores.
- Demographic Snapshot: The cohort was primarily comprised of women between the ages of 40 and 59 (mean age 52.1). The majority identified as white (62.7%), and 96.5% of the group utilized transdermal estradiol, a common form of HT that bypasses the liver and delivers steady levels of hormone through the skin.
Notably, the researchers performed subgroup analyses to see if factors such as race, age, menopause stage, or existing history of depression/anxiety altered the efficacy of the treatment. They found no significant differences, suggesting that the psychological benefits of HT may be broadly applicable across diverse patient profiles.
The Biochemical Bridge: Why Hormones Impact Mood
To understand why hormone therapy might alleviate mood disorders, one must look at the brain. Estrogen is not merely a reproductive hormone; it is a neurosteroid that influences neurotransmitter systems, including serotonin, dopamine, and norepinephrine.
"Low estrogen status has been linked to metabolic and functional changes in brain structure and activity," the authors noted. Conversely, estrogen repletion has been associated with improved cortical blood flow and the partial reversal of serotonin imbalances—a key chemical messenger involved in mood regulation.
While the medical community has long acknowledged that menopausal symptoms vary by demographic and life circumstances, the "slew of mental symptoms" reported by 60% to 86% of women has historically been treated through a fragmented lens. Patients are often shunted toward antidepressants or anti-anxiety medications without addressing the underlying endocrine shift that may be the primary driver of their psychological distress.
Official Responses and the Need for Caution
While the findings from Dr. Fairweather and her team are promising, the medical establishment is urging a measured interpretation. JoAnn E. Manson, MD, MPH, DrPH, of Harvard Medical School and a past president of The Menopause Society, emphasized that while these results support the growing body of evidence linking estrogen to mood regulation, they do not constitute a "final word."
"We need additional randomized trial research on the effects of different formulations of hormone therapy on mood and other mental health outcomes," Dr. Manson told MedPage Today. "This is an important study for generating hypotheses, but its observational nature precludes cause-and-effect conclusions."
The distinction is critical. Because this was a retrospective study, it lacks the rigor of a placebo-controlled, double-blind trial. Researchers cannot rule out the possibility of a "placebo effect" or other confounding factors that might influence how a patient reports their mood after starting a new treatment. Furthermore, the study population was largely commercially insured and used a single primary type of estradiol, which limits the ability to generalize these results to the entire global population of menopausal women.
Clinical Implications: A Paradigm Shift?
The central tension highlighted by this research is the disconnect between FDA labeling and clinical reality. Currently, systemic estrogen with progestogen is FDA-approved for the management of vasomotor symptoms (hot flashes), the treatment of genitourinary syndrome of menopause, and the prevention of osteoporosis. It is not officially approved for the treatment of mood disorders.
"It is not FDA-approved for treating mood-related symptoms, and no current consensus exists on standardized screening or treatment protocols for mood disturbances during the menopause transition," the authors wrote.
This creates a vacuum in clinical care. If a woman presents with severe irritability and anxiety as her primary menopausal complaint, her physician currently lacks a clear, evidence-based protocol that prioritizes hormone therapy as a first-line treatment for those specific symptoms.
Moving Forward
The researchers hope their work will spark a change in how menopause is viewed in the exam room. They argue that hormone therapy should be considered a cornerstone of a "comprehensive approach" to midlife health. By moving beyond the traditional focus on vasomotor complaints, providers may be able to address the "overall menopausal symptom burden" more effectively.
For the patient, this means the potential for a more integrated care model. Rather than treating physical symptoms and psychological symptoms as separate entities—often handled by different specialists—the study advocates for a holistic view of the menopause transition.
As the medical community continues to parse the data, the path forward appears clear: while more randomized, long-term clinical trials are necessary to solidify these findings, the "real-world" experience of these 260 women provides a compelling argument that for many, the path to emotional stability may lie in the very hormones that were once thought to be only for the hot flashes.
For now, the message to clinicians is to keep an open mind, continue monitoring the emerging evidence, and ensure that when a patient describes the "fog" and the "irritability" of menopause, their concerns are treated with the same clinical weight as the physical symptoms that have long dominated the menopause conversation.
